Dr Jeffery Matous at ASH 2014: Phase I MM-008 study of pomalidomide and dexamethasone in relapsed/refractory myeloma with renal impairment

Dr Jeffery Matous at ASH 2014: Phase I MM-008 study of pomalidomide and dexamethasone in relapsed/refractory myeloma with renal impairment

EMJ

4 years
946 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses combination approaches and novel monoclonal antibodies in multiple myeloma. The phase I MM-008 study is assessing the pharmacokinetics and safety of pomalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma and renal impairment.
Up Next Autoplay
Who is Eligible for the AVIATOR Study? @SeattleCCA
Who is Eligible for the AVIATOR Study? @SeattleCCA
Category: Breast Cancer
1 Views
SeattleCCA 1 hour
The AVIATOR Study @SeattleCCA
The AVIATOR Study @SeattleCCA
Category: Breast Cancer
0 Views
SeattleCCA 2 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 5 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 5 hours